Harry Thomasian Jr. serves as the Chief Financial Officer at PRECIGEN INC, a biotechnology company focused on developing innovative gene and cell therapies. With a robust background in finance and strategic planning, Thomasian has been instrumental in guiding PRECIGEN through its growth phases. Prior to joining PRECIGEN, he held several high-level financial positions at various companies, showcasing his expertise in managing complex financial operations and driving corporate strategy. Thomasian's career is marked by significant achievements in the financial sector, particularly within the biotechnology industry. Before his role at PRECIGEN, he served as CFO at Intrexon Corporation, where he played a key role in the company's expansion and financial stability. His strategic financial planning and keen insight into market trends have enabled him to successfully navigate the challenges of the biotech industry. Thomasian holds a degree in Finance from a prestigious university, which has provided him with a strong foundation to excel in his role. As CFO at PRECIGEN, Harry Thomasian Jr. is responsible for overseeing the company's financial operations, including budgeting, forecasting, and financial reporting. His leadership has been pivotal in securing funding for PRECIGEN's research and development initiatives, ensuring the company remains at the forefront of gene and cell therapy innovation. Thomasian's commitment to excellence and his ability to foster strong relationships with investors and stakeholders have significantly contributed to PRECIGEN's success and reputation in the biotechnology sector.